Biological confounders for the values of cerebrospinal fluid
proteins in Parkinson's disease and related disorders

J 2016

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

MOLLENHAUER, Brit, Lucilla PARNETTI, Irena REKTOROVÁ, Milica G. KRAMBERGER, Maria PIKKARAINEN et. al.

Basic information

Original name

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

Authors

MOLLENHAUER, Brit (276 Germany), Lucilla PARNETTI (380 Italy), Irena REKTOROVÁ (203 Czech Republic, guarantor, belonging to the institution), Milica G. KRAMBERGER (705 Slovenia), Maria PIKKARAINEN (246 Finland), Walter J. SCHULZ-SCHAEFFER (276 Germany), Dag AARSLAND (752 Sweden), Per SVENNINGSSON (752 Sweden), Lucia FAROTTI (380 Italy), Marcel M. VERBEEK (528 Netherlands) and Michael G. SCHLOSSMACHER (124 Canada)

Edition

Journal of Neurochemistry, HOBOKEN, WILEY-BLACKWELL, 2016, 0022-3042

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.083

RIV identification code

RIV/00216224:14740/16:00092576

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1111/jnc.13390

UT WoS

000385770500019

Keywords in English

cerebrospinal fluid biomarker; confounding; factors; dementia; neuropathology; Parkinson's disease; -synuclein; -amyloid; tau-protein

Abstract

V originále

Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. In Alzheimer's disease, levels of increased CSF tau protein and decreased levels of -amyloid 1-42 (A42) have been shown to correlate with brain plaque formation and tangle pathology. Intracellular Lewy inclusions containing aggregated -synuclein (-syn) represent a pathological hallmark of Parkinson's disease (PD). In most - but not all - studies published to date total CSF -syn concentrations have been found to be decreased in disorders related to -syn pathology, that is, PD, dementia with Lewy bodies and multiple system atrophy. However, these reports show extensive signal overlap among tested individuals, thereby diminishing its potential for routine use in clinical practice. To investigate potential biological (i.e., non-technical) confounders of reported CSF levels for -syn, A42, and tau in PD and related disorders, we carried out a methodical review of known factors that underlie signal variability and speculate on those that have not yet been tested. We discuss several biological factors, such as neuropathology, demographics, clinical phenotype, progression and duration of disease, concomitant illnesses and, last but not least, pharmacotherapy, which in isolation or combination can substantially alter values for CSF proteins of interest. Enhanced implementation of standardized clinical protocols, streamlined operating procedures, and further progress in the development of validated assays for CSF proteins have the potential to (i) inform us as to the pathogenesis of disease, (ii) support the laboratory-based diagnosis for symptomatic subjects in the future, and (iii) facilitate breakthrough therapies to alter the course of neurodegenerative disorders, such as PD and Alzheimer's disease. Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. To investigate potential biological confounders of reported CSF levels for -synuclein (-Syn), amyloid- 1-42(A42) and tau protein in Parkinson's disease and related disorders, we reviewed the current literature for known factors that underlie signal variability and speculate on those that have not yet been tested. This article is part of a .

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

Citovat

MOLLENHAUER, Brit, Lucilla PARNETTI, Irena REKTOROVÁ, Milica G. KRAMBERGER, Maria PIKKARAINEN, Walter J. SCHULZ-SCHAEFFER, Dag AARSLAND, Per SVENNINGSSON, Lucia FAROTTI, Marcel M. VERBEEK and Michael G. SCHLOSSMACHER. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry. HOBOKEN: WILEY-BLACKWELL, 2016, vol. 139, October, p. 290-317. ISSN 0022-3042. Available from: https://dx.doi.org/10.1111/jnc.13390.

@article{1366204,
   author = {Mollenhauer, Brit and Parnetti, Lucilla and Rektorová, Irena and Kramberger, Milica G. and Pikkarainen, Maria and SchulzandSchaeffer, Walter J. and Aarsland, Dag and Svenningsson, Per and Farotti, Lucia and Verbeek, Marcel M. and Schlossmacher, Michael G.},
   article_location = {HOBOKEN},
   article_number = {October},
   doi = {http://dx.doi.org/10.1111/jnc.13390},
   keywords = {cerebrospinal fluid biomarker; confounding; factors; dementia; neuropathology; Parkinson's disease; -synuclein; -amyloid; tau-protein},
   language = {eng},
   issn = {0022-3042},
   journal = {Journal of Neurochemistry},
   title = {Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders},
   url = {http://onlinelibrary.wiley.com/doi/10.1111/jnc.13390/epdf},
   volume = {139},
   year = {2016}
}

TY  - JOUR
ID  - 1366204
AU  - Mollenhauer, Brit - Parnetti, Lucilla - Rektorová, Irena - Kramberger, Milica G. - Pikkarainen, Maria - Schulz-Schaeffer, Walter J. - Aarsland, Dag - Svenningsson, Per - Farotti, Lucia - Verbeek, Marcel M. - Schlossmacher, Michael G.
PY  - 2016
TI  - Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
JF  - Journal of Neurochemistry
VL  - 139
IS  - October
SP  - 290-317
EP  - 290-317
PB  - WILEY-BLACKWELL
SN  - 00223042
KW  - cerebrospinal fluid biomarker
KW  - confounding
KW  - factors
KW  - dementia
KW  - neuropathology
KW  - Parkinson's disease
KW  - -synuclein
KW  - -amyloid
KW  - tau-protein
UR  - http://onlinelibrary.wiley.com/doi/10.1111/jnc.13390/epdf
L2  - http://onlinelibrary.wiley.com/doi/10.1111/jnc.13390/epdf
N2  - Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. In Alzheimer's disease, levels of increased CSF tau protein and decreased levels of -amyloid 1-42 (A42) have been shown to correlate with brain plaque formation and tangle pathology. Intracellular Lewy inclusions containing aggregated -synuclein (-syn) represent a pathological hallmark of Parkinson's disease (PD). In most - but not all - studies published to date total CSF -syn concentrations have been found to be decreased in disorders related to -syn pathology, that is, PD, dementia with Lewy bodies and multiple system atrophy. However, these reports show extensive signal overlap among tested individuals, thereby diminishing its potential for routine use in clinical practice. To investigate potential biological (i.e., non-technical) confounders of reported CSF levels for -syn, A42, and tau in PD and related disorders, we carried out a methodical review of known factors that underlie signal variability and speculate on those that have not yet been tested. We discuss several biological factors, such as neuropathology, demographics, clinical phenotype, progression and duration of disease, concomitant illnesses and, last but not least, pharmacotherapy, which in isolation or combination can substantially alter values for CSF proteins of interest. Enhanced implementation of standardized clinical protocols, streamlined operating procedures, and further progress in the development of validated assays for CSF proteins have the potential to (i) inform us as to the pathogenesis of disease, (ii) support the laboratory-based diagnosis for symptomatic subjects in the future, and (iii) facilitate breakthrough therapies to alter the course of neurodegenerative disorders, such as PD and Alzheimer's disease. Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. To investigate potential biological confounders of reported CSF levels for -synuclein (-Syn), amyloid- 1-42(A42) and tau protein in Parkinson's disease and related disorders, we reviewed the current literature for known factors that underlie signal variability and speculate on those that have not yet been tested. This article is part of a .
ER  -

MOLLENHAUER, Brit, Lucilla PARNETTI, Irena REKTOROVÁ, Milica G. KRAMBERGER, Maria PIKKARAINEN, Walter J. SCHULZ-SCHAEFFER, Dag AARSLAND, Per SVENNINGSSON, Lucia FAROTTI, Marcel M. VERBEEK and Michael G. SCHLOSSMACHER. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. \textit{Journal of Neurochemistry}. HOBOKEN: WILEY-BLACKWELL, 2016, vol.~139, October, p.~290-317. ISSN~0022-3042. Available from: https://dx.doi.org/10.1111/jnc.13390.

Detailed Information on Publication Record